Measuring vitamin B12 deficiency properly: why the serum value can mislead

You are sitting in the consulting room. The printout lies on the table. Vitamin B12: 310 picograms per millilitre. All in the green.

And still your left foot falls asleep at night. You search for words that used to simply be there. You are tired in the morning even after eight hours in bed. You have no explanation, and now there is a number saying: it is not this.

I know this conversation. And I would like to ask you an uncomfortable question. What if the number is not measuring the thing you are actually looking for?

This is no criticism of the lab and no criticism of your doctor. Total B12 in serum is an established, sensible first-line test. It simply has one property that is far too rarely mentioned. It responds late, and it measures something other than what arrives in your nerve cell.

Two taxis, two destinations: why your total value can point the wrong way

Picture your blood as a city. Vitamin B12 does not drive itself around in it. It sits in taxis.

There are two taxi companies. One is called haptocorrin. The other is called transcobalamin. Both carry the same molecule. They simply drive to completely different addresses.

Haptocorrin taxis drive to the liver. There the B12 is taken up and pulled out of circulation. Transcobalamin taxis drive to all the other cells: to your nerve cells, to your bone marrow, to your gut lining. Only this second fraction is what specialists call active B12, holo-TC or holo-transcobalamin for short.

And here is the point where the lab sheet goes blurry. When your lab measures vitamin B12, it counts both taxi companies together. The larger part of the journeys belongs to haptocorrin. The result can therefore be dominated by a fraction that matters little to your nerves.

There is a second problem on top, and it has nothing to do with genetics. It has to do with order. The body does not empty its B12 accounts at the same time. It empties them one after the other.

The common model for this describes an order. First the active transport fraction can shrink. Then metabolic products can pile up, because the enzymes in the cell no longer get enough cofactor. Only after that can the total value drop below the range, and last of all the blood count can change. This staged model is well established, but the exact cut-offs are still discussed in the field. Whoever measures only the total value is, according to this model, watching the third leg of a race that was already decided in the first.

And now you know why the next question is not "is my value normal" but "which value did we actually measure".

The stepwise diagnostics: holo-TC, methylmalonic acid, homocysteine

With vitamin B12 there is no single test that settles everything. The British professional society for haematology puts this remarkably openly in its guideline: there is no gold standard that defines a deficiency, and the clinical picture remains the most important factor when test results are assessed.

That sounds frustrating at first. I find it freeing. It takes away the power of one number to pass judgement on your complaints, and gives it back to the whole picture.

If no single test is enough, you work in steps. This is what the logic looks like.

Holo-TC: a look at what is allowed to travel

Holo-TC measures exactly the taxi fraction that drives to your cells. Because this share can fall first, it can show a deficiency earlier than the total value. The data behind this is decent, but not overwhelming.

A larger dataset from clinical routine arrives at a similar picture. In an analysis of 3,614 samples sent in to a laboratory, in which all four markers were measured at the same time, holo-TC came out best among the single markers. This figure has to be read carefully: the yardstick was a calculated formula that holo-TC itself feeds into, and the samples came from laboratory routine rather than from a random sample of the population. What is robust about this work is above all one thing: two markers from two levels together can show more than any single value, in particular holo-TC together with methylmalonic acid.

A smaller study of 217 people at a hospital in India shows how full this grey zone can be. In the group with borderline total B12, which is exactly the range where many results land, 34 percent had a low holo-TC and 28 percent a raised homocysteine. Context belongs with this: in India a B12 deficiency is considerably more common than here, and how many hits a test produces depends directly on how common the thing you are looking for is in the group examined. These proportions therefore do not transfer one to one to Germany. The direction stays instructive all the same: the grey zone is not empty.

Methylmalonic acid: the functional marker

Now it gets interesting, because MMA asks a different question. Not "how much B12 is swimming in the blood", but "is the B12-dependent metabolism working inside your cell".

Vitamin B12 is the cofactor for an enzyme in your mitochondria. This enzyme converts methylmalonyl-CoA further. If the cofactor is missing, the precursor backs up, and methylmalonic acid appears in blood and urine. Picture it as a traffic jam in front of a half-closed barrier. You do not see the barrier, you see the queue of cars.

Homocysteine: sensitive, but talkative about many things

Homocysteine rises when methylation stalls. Vitamin B12 is part of that pathway, so a deficiency can drive the value up. Only B12 is not the sole reason. Folate deficiency, vitamin B6 deficiency, kidney weakness, an underactive thyroid, age and some medicines can have the same effect.

The British guideline therefore places homocysteine as a possible second-line marker that is less specific than methylmalonic acid. Useful as a piece of the puzzle, not sufficient as proof.

And now you know why a single number cannot answer this question.

Vitamin B12 deficiency symptoms: from the blood count to the nervous system

Perhaps you know this moment. You describe a tingling in your feet. And because the blood count looks unremarkable, vitamin B12 understandably moves further down the list of possibilities. Understandably, because the coupling between blood count and nerve was regarded as tight for decades.

Before we go further, one sentence belongs here, the one I say first in the consulting room. A tingling in the feet has many possible causes, and vitamin B12 is only one of them. More common are nerve damage in diabetes, a link with regular alcohol use, an underactive thyroid, carpal tunnel syndrome, an irritated nerve root or a condition such as multiple sclerosis. An enlarged mean cell volume in the blood count can also have reasons other than B12, for example alcohol, liver disease, an underactive thyroid, certain medicines or a disorder of the bone marrow. That belongs in a medical work-up before you settle on a single nutrient. This article describes one possibility that is often checked too late. It does not describe the most likely one.

And this is where one of the most stubborn misunderstandings sits.

Vitamin B12 works on two separate building sites. In blood formation it takes part in DNA synthesis. If it is missing, the precursor cells divide too slowly while they keep growing. The result is few, oversized red blood cells. That is megaloblastic anaemia, with pallor, breathlessness on exertion and exhaustion.

In the nerves it is about something else: about methylation and therefore about the upkeep of the myelin sheath, the insulating layer around the nerve fibre. When this layer suffers, the signal can no longer run cleanly. Tingling, numbness, unsteadiness when walking in the dark, trouble finding words, low mood.

These two building sites do not always move in step. They can come apart, and that is exactly what makes this difficult. In the classic study on this, most of those affected did also have a change in the blood count. But not all of them. And for those whose blood count stays quiet, the road to a diagnosis is often very long.

How common is all this? The large international review in the journal Nature Reviews Disease Primers places it like this: the classic full-blown deficiency with blood count changes and neurology is relatively rare. Subclinical deficiency, by contrast, affects between 2.5 and 26 percent of the general population, depending on the definition used. How clinically relevant this subclinical range is, the authors themselves describe as unclear.

I find this honesty important. It protects against two errors at once: against dramatising every borderline value, and against brushing off real complaints.

And now you know why I do not look only at the blood count when hands or feet tingle.

Who carries a higher risk, and why this concerns more people today

Vitamin B12 has a peculiarity that sets it apart from almost every other vitamin. The route from the plate into the cell is unusually complicated.

The vitamin has to be released from food protein in the stomach, which needs stomach acid and pepsin. Then it has to bind to intrinsic factor, a protein from the parietal cells of the stomach. This pair travels down to the last section of the small intestine, where it is taken up through its own receptor. Every one of these steps can fail.

That is why a B12 deficiency is often not an intake problem but an absorption problem. And exactly that leads to the risk groups.

Two of these points I would like to back with numbers, because they concern a great many people.

On plant-based eating the data is clear in direction and restless in its numbers. Two systematic reviews found high proportions of people with a low B12 status across all age groups, with very wide ranges depending on the group studied, the country and the measurement method. The core stays the same: anyone eating purely plant-based who neither supplements nor uses fortified foods such as plant drinks or nutritional yeast should assume that intake is not sufficient. That is not a verdict on the way of eating, it is a question of where this one molecule comes from.

And then there is a risk group that appeared in no textbook chapter twenty years ago.

In older age everything comes together. A French review describes that more than twenty percent of older people can be affected, and that in this group food-cobalamin malabsorption is the most common cause, considerably more common than classic pernicious anaemia.

For me this is one of the reasons why targeted topping up can be justified more often today than it used to be. Not because supplements are in fashion. But because the background conditions may have shifted: longer stretches of long-term medication, a higher share of highly processed foods, more people eating purely plant-based, an ageing population. That is my assessment from practice and not a proven chain of cause and effect. In no individual case does it replace measuring.

And now you know why, with an abnormal B12 value, I always ask what you take regularly.

The homeostasis point: how folic acid can mask a B12 deficiency

If you take only one single thought away from this text, please let it be this one.

Vitamin B12 and folate work at the same junction. Both are needed so the cell can pass methyl groups along. When B12 is missing, folate gets stuck in a dead end, and the DNA building blocks for blood formation run short. That is exactly how megaloblastic anaemia arises.

Now comes the point that is so often missing in counselling. If high-dose folic acid is given in this situation, blood formation can start up again. The big, obvious warning signal can disappear as a result. The B12-dependent upkeep of the nerve sheath gets nothing from it, though, as far as we understand it today. The alarm is quieter, the fire is not.

This concern is old. It comes from a time when pernicious anaemia was treated with folic acid and it was observed that blood values improved while the neurological deficits progressed. An experiment on this would be unethical today. Modern interpretation therefore rests on observational data, and that has to be labelled honestly as such.

For me this is the teaching example par excellence for how to handle supplements. The body regulates nutrients in loops, not in separate drawers. Whoever turns one screw automatically moves others.

The same pattern meets you in many places. Zinc at high doses over months can push down copper absorption. With high-dose vitamin D it is debated whether magnesium and vitamin K2 should be considered alongside, and solid studies on this are so far missing. Iron given during silent inflammation can run into nothing. A nutrient is not a switch. It is a player in a network.

And now you know why, with a combination product, I always ask first what else is in it.

The four lenses: why B12 plays a part everywhere at once

In clinical psychoneuroimmunology we look at a symptom through four lenses. Vitamin B12 is a good example of why that is not a detour but simply cell biology.

These four lenses explain why vitamin B12 turns up in such different contexts: with exhaustion, with tingling, with memory questions, with anaemia, with a burning tongue. Not because it would be a remedy for everything. But because a cofactor sitting at two central enzymes can make itself felt in many places when it runs short.

Meeting requirements or therapy: why the dose changes the category

Now to a distinction that blurs completely on the shelf and decides everything in medicine.

On one side stands meeting requirements. These are the amounts you need so that normal metabolism runs. The European Food Safety Authority gives an adequate intake of 4 micrograms of vitamin B12 per day for adults. No tolerable upper level was set, because the available data allowed no threshold for harmful effects to be derived. That is explicitly not a free pass, it is the description of a data gap.

On the other side stands therapeutic use. Here a nutrient is no longer used to top up, but in a targeted way, at high dose, for a limited time and under monitoring. With vitamin B12 there is an example of this that almost caricatures the difference.

This example stands here explicitly not as a recommendation but as an illustration of a principle. Orthomolecular, that is therapeutic high-dose use, is something completely different from meeting requirements with a capsule from an online shop. It has an indication, monitoring, an endpoint and a medical responsibility. Whoever leaves out these four things and copies only the number is doing something fundamentally different from what was in the study.

Between these two poles lies the everyday question. Tablet or injection?

Before we talk about products, one sentence belongs at the start, one I say in every conversation. Real food from good sources comes first. Vitamin B12 sits in meat, organ meats, eggs, dairy products and in small fish such as sardine or herring. One restriction applies to liver: in pregnancy it is advised against, because it contains a great deal of vitamin A. Large predatory fish I deliberately leave out, because of mercury, in organic quality too. Foods deliver nutrients together with many accompanying substances, and much about that is still not understood. A capsule does not reproduce it. With vitamin B12 there is one exception worth knowing, though: if absorption in the stomach is disturbed, free B12 from a preparation can actually arrive better than the protein-bound form from food.

And at the same time this holds: with a purely plant-based diet, after stomach surgery or with an autoimmune gastritis, no plate in the world is a solution. These are the well-founded exceptions in which substitution can make sense not for a limited time but permanently. That is exactly why they are exceptions and not the rule.

And now you know why the question "how much B12 should I take" is hard to answer without the question "why is it missing in you".

Three levers you can act on today

No protocols, no brands, no dosing plans. Just three things that lie in your hands and that make a conversation in the practice better.

And now you know why a value inside the reference range is sometimes the beginning of a question and not its end.

Common questions about vitamin B12 deficiency and how it is measured

How this topic connects with the others

Vitamin B12 rarely stands alone. If you feel that one building block is not enough, these paths lead further.